Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2025 | Challenges to implementing multimodal AI models in routine clinical practice

Joseph Sparano • 10 Dec 2025
SABCS 2025
Breast Cancer

Joseph Sparano, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses key challenges in developing novel diagnostic tests through public-private partnerships in oncology research. Dr Sparano highlights the importance of collaborations between publicly funded research groups, which provide access to trial participants, clinical outcome data, and biospecimens, and companies with expertise in diagnostic test development. He emphasizes the need for cohorts large enough to train AI models and perform external validation in independent populations. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2025 Meeting in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Joseph Sparano

Multimodal AI predicts breast cancer recurrence in TAILORx
2:13
Multimodal AI predicts breast cancer recurrence in TAILORx
Joseph Sparano • 10 Dec 2025
Addressing health disparities in AI development for breast cancer
1:27
Addressing health disparities in AI development for breast cancer
Joseph Sparano • 10 Dec 2025
TAILORx: an update incl 12-year event rates in woman with ER+ lymph node-negative breast cancer
5:19
TAILORx: an update incl 12-year event rates in woman with ER+ lymph node-negative breast cancer
Joseph Sparano • 7 Dec 2022
Racial disparities in breast cancer and metastasis and possible contributing biological factors
4:39
Racial disparities in breast cancer and metastasis and possible contributing biological factors
Joseph Sparano • 7 Dec 2022

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals